Jim Cramer on GRAIL: "Don't Call Yourself Early if You're Buying This One"

GRAIL, Inc. (NASDAQ:GRAL) is one of the stocks Jim Cramer put under the spotlight recently. Cramer noted the company’s huge run for the year and stated:

“And there’s Grail, a company that has a blood test that can detect cancer, maybe. It’s just got a readout for how the test works, and the results were mixed to positive. Grail immediately took advantage of the huge spike on the news… to do a private placement of $325 million. Now, I’m intrigued by the technology, but the company’s been losing hundreds of millions of dollars in the last five years, and the stock is up 347% for the year. Don’t call yourself early if you’re buying this one, even as the stock has pulled back from $103 to $79 over the past two days.”

Stock market reports printed on a sheet of paper. Photo by RDNE Stock Project on Pexels GRAIL, Inc. (NASDAQ:GRAL) develops and markets blood-based tests for early cancer detection, including its Galleri screening test for multiple cancers. On October 21, when a caller inquired about the stock, Cramer showed bearish sentiment and said:

“Yeah, and I just read a really good piece the other day written by Dr. Topol, who’s been on the show a number of times. It did not make me feel that it was worth a, you know, I just didn’t think it was worth owning after this very big parabolic move. I’m going to say absolutely not to that one.”

While we acknowledge the potential of GRAL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.